|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
|
|
2
|
Spadi R, Brusa F, Ponzetti A, Chiappino I,
Birocco N, Ciuffreda L and Satolli MA: Current therapeutic
strategies for advanced pancreatic cancer: A review for clinicians.
World J Clin Oncol. 7:27–43. 2016.
|
|
3
|
Neoptolemos JP, Ghaneh P and Hackert T:
Multimodality standard of care treatment of resectable and
borderline resectable pancreatic cancer. Hepatobiliary Surg Nutr.
10:714–716. 2021.
|
|
4
|
Wang Z, Li Y, Ahmad A, Banerjee S, Azmi
AS, Kong D and Sarkar FH: Pancreatic cancer: Understanding and
overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 8:27–33.
2011.
|
|
5
|
Ducreux M, Cuhna AS, Caramella C,
Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van
Laethem JL, Conroy T, et al: Cancer of the pancreas: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 26(Suppl 5): v56–v68. 2015.
|
|
6
|
Conroy T, Hammel P, Hebbar M, Abdelghani
MB, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, et
al: FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic
cancer. N Engl J Med. 379:2395–2406. 2018.
|
|
7
|
Ding R, Shi J, Pabon K and Scotto KW:
Xanthines down-regulate the drug transporter ABCG2 and reverse
multidrug resistance. Mol Pharmacol. 81:328–337. 2012.
|
|
8
|
Kwatra D, Venugopal A, Standing D,
Ponnurangam S, Dhar A, Mitra A and Anant S: Bitter melon extracts
enhance the activity of chemotherapeutic agents through the
modulation of multiple drug resistance. J Pharm Sci. 102:4444–4454.
2013.
|
|
9
|
Lyn-Cook BD, Rogers T, Yan Y, Blann EB,
Kadlubar FF and Hammons GJ: Chemopreventive effects of tea extracts
and various components on human pancreatic and prostate tumor cells
in vitro. Nutr Cancer. 35:80–86. 1999.
|
|
10
|
Behrens M and Meyerhof W: Bitter taste
receptors and human bitter taste perception. Cell Mol Life Sci.
63:1501–1509. 2006.
|
|
11
|
Adler E, Hoon MA, Mueller KL,
Chandrashekar J, Ryba NJ and Zuker CS: A novel family of mammalian
taste receptors. Cell. 100:693–702. 2000.
|
|
12
|
Meyerhof W, Batram C, Kuhn C, Brockhoff A,
Chudoba E, Bufe B, Appendino G and Behrens M: The molecular
receptive ranges of human TAS2R bitter taste receptors. Chem
Senses. 35:157–170. 2010.
|
|
13
|
Zehentner S, Reiner AT, Grimm C and Somoza
V: The role of bitter taste receptors in cancer: A systematic
review. Cancers (Basel). 13:58912021.
|
|
14
|
Jeruzal-Swiatecka J, Fendler W and
Pietruszewska W: Clinical role of extraoral bitter taste receptors.
Int J Mol Sci. 21:51562020.
|
|
15
|
Gaida MM, Mayer C, Dapunt U, Stegmaier S,
Schirmacher P, Wabnitz GH and Hänsch GM: Expression of the bitter
receptor T2R38 in pancreatic cancer: Localization in lipid droplets
and activation by a bacteria-derived quorum-sensing molecule.
Oncotarget. 7:12623–12632. 2016.
|
|
16
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002.
|
|
17
|
Stern L, Giese N, Hackert T, Strobel O,
Schirmacher P, Felix K and Gaida MM: Overcoming chemoresistance in
pancreatic cancer cells: Role of the bitter taste receptor T2R10. J
Cancer. 9:711–725. 2018.
|
|
18
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002.
|
|
19
|
Mundi PS, Sachdev J, McCourt C and
Kalinsky K: AKT in cancer: New molecular insights and advances in
drug development. Br J Clin Pharmacol. 82:943–956. 2016.
|
|
20
|
Mo W and Zhang JT: Human ABCG2: Structure,
function, and its role in multidrug resistance. Int J Biochem Mol
Biol. 3:1–27. 2012.
|
|
21
|
Doyle L and Ross DD: Multidrug resistance
mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 22:7340–7358. 2003.
|
|
22
|
Medapati MR, Singh N, Bhagirath AY, Duan
K, Triggs-Raine B, Batista EL Jr and Chelikani P: Bitter taste
receptor T2R14 detects quorum sensing molecules from cariogenic
Streptococcus mutans and mediates innate immune responses in
gingival epithelial cells. FASEB J. 35:e213752021.
|
|
23
|
Medapati MR, Bhagirath AY, Singh N,
Schroth RJ, Bhullar RP, Duan K and Chelikani P: Bitter taste
receptor T2R14 modulates gram-positive bacterial internalization
and survival in gingival epithelial cells. Int J Mol Sci.
22:99202021.
|
|
24
|
Hariri BM, McMahon DB, Chen B, Freund JR,
Mansfield CJ, Doghramji LJ, Adappa ND, Palmer JN, Kennedy DW, Reed
DR, et al: Flavones modulate respiratory epithelial innate
immunity: Anti-inflammatory effects and activation of the T2R14
receptor. J Biol Chem. 292:8484–8497. 2017.
|
|
25
|
Singh N, Chakraborty R, Bhullar RP and
Chelikani P: Differential expression of bitter taste receptors in
non-cancerous breast epithelial and breast cancer cells. Biochem
Biophys Res Commun. 446:499–503. 2014.
|
|
26
|
Singh N, Shaik FA, Myal Y and Chelikani P:
Chemosensory bitter taste receptors T2R4 and T2R14 activation
attenuates proliferation and migration of breast cancer cells. Mol
Cell Biochem. 465:199–214. 2020.
|
|
27
|
Carey RM, Kim T, Cohen NA, Lee RJ and Nead
KT: Impact of sweet, umami, and bitter taste receptor (TAS1R and
TAS2R) genomic and expression alterations in solid tumors on
survival. Sci Rep. 12:89372022.
|
|
28
|
Dagan-Wiener A, Di Pizio A, Nissim I,
Bahia MS, Dubovski N, Margulis E and Niv MY: BitterDB: Taste
ligands and receptors database in 2019. Nucleic Acids Res.
47:D1179–D1185. 2019.
|
|
29
|
Meyer H, Bolarinwa A, Wolfram G and
Linseisen J: Bioavailability of apigenin from apiin-rich parsley in
humans. Ann Nutr Metab. 50:167–172. 2006.
|
|
30
|
Hostetler GL, Ralston RA and Schwartz SJ:
Flavones: Food sources, bioavailability, metabolism, and
bioactivity. Adv Nutr. 8:423–435. 2017.
|
|
31
|
Zhang J, Liu D, Huang Y, Gao Y and Qian S:
Biopharmaceutics classification and intestinal absorption study of
apigenin. Int J Pharm. 436:311–317. 2012.
|
|
32
|
Birt DF, Walker B, Tibbels MG and Bresnick
E: Anti-mutagenesis and anti-promotion by apigenin, robinetin and
indole-3-carbinol. Carcinogenesis. 7:959–963. 1986.
|
|
33
|
Imran M, Gondal TA, Atif M, Shahbaz M,
Qaisarani TB, Mughal MH, Salehi B, Martorell M and Sharifi-Rad J:
Apigenin as an anticancer agent. Phytother Res. 34:1812–1828.
2020.
|
|
34
|
Ashrafizadeh M, Bakhoda MR, Bahmanpour Z,
Ilkhani K, Zarrabi A, Makvandi P, Khan H, Mazaheri S, Darvish M and
Mirzaei H: Apigenin as tumor suppressor in cancers: Biotherapeutic
activity, nanodelivery, and mechanisms with emphasis on pancreatic
cancer. Front Chem. 8:8292020.
|
|
35
|
Ujiki MB, Ding XZ, Salabat MR, Bentrem DJ,
Golkar L, Milam B, Talamonti MS, Bell RH Jr, Iwamura T and Adrian
TE: Apigenin inhibits pancreatic cancer cell proliferation through
G2/M cell cycle arrest. Mol Cancer. 5:762006.
|
|
36
|
King JC, Lu QY, Li G, Moro A, Takahashi H,
Chen M, Go VLW, Reber HA, Eibl G and Hines OJ: Evidence for
activation of mutated p53 by apigenin in human pancreatic cancer.
Biochim Biophys Acta. 1823:593–604. 2012.
|
|
37
|
Strouch MJ, Milam BM, Melstrom LG, McGill
JJ, Salabat MR, Ujiki MB, Ding XZ and Bentrem DJ: The flavonoid
apigenin potentiates the growth inhibitory effects of gemcitabine
and abrogates gemcitabine resistance in human pancreatic cancer
cells. Pancreas. 38:409–415. 2009.
|
|
38
|
Lee SH, Ryu JK, Lee KY, Woo SM, Park JK,
Yoo JW, Kim YT and Yoon YB: Enhanced anti-tumor effect of
combination therapy with gemcitabine and apigenin in pancreatic
cancer. Cancer Lett. 259:39–49. 2008.
|
|
39
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA:
The 2019 WHO classification of tumours of the digestive system.
Histopathology. 76:182–188. 2020.
|
|
40
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.
|
|
41
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
42
|
Singh N, Shaik FA, Myal Y and Chelikani P:
Chemosensory bitter taste receptors T2R4 and T2R14 activation
attenuates proliferation and migration of breast cancer cells. Mol
Cell Biochem. 465:199–214. 2020.
|
|
43
|
Cao SS and Zhen YS: Potentiation of
antimetabolite antitumor activity in vivo by dipyridamole and
amphotericin B. Cancer Chemother Pharmacol. 24:181–186. 1989.
|
|
44
|
Hebenstreit D, Fang M, Gu M, Charoensawan
V, van Oudenaarden A and Teichmann SA: RNA sequencing reveals two
major classes of gene expression levels in metazoan cells. Mol Syst
Biol. 7:4972011.
|
|
45
|
Wagner GP, Kin K and Lynch VJ: A model
based criterion for gene expression calls using RNA-seq data.
Theory Biosci. 132:159–164. 2013.
|
|
46
|
He J, Ning C, Wang Y, Huang H, Ge Y, Liu J
and Jiang Y: Natural plant flavonoid apigenin directly disrupts
Hsp90/Cdc37 complex and inhibits pancreatic cancer cell growth and
migration. J Functional Foods. 18:10–21. 2015.
|
|
47
|
Lieber M, Mazzetta J, Nelson-Rees W,
Kaplan M and Todaro G: Establishment of a continuous tumor-cell
line (panc-1) from a human carcinoma of the exocrine pancreas. Int
J Cancer. 15:741–747. 1975.
|
|
48
|
Drucker BJ, Marincola FM, Siao DY, Donlon
TA, Bangs CD and Holder WD Jr: A new human pancreatic carcinoma
cell line developed for adoptive immunotherapy studies with
lymphokine-activated killer cells in nude mice. In Vitro Cell Dev
Biol. 24:1179–1187. 1988.
|
|
49
|
Lambert A, Gavoille C and Conroy T:
Current status on the place of FOLFIRINOX in metastatic pancreatic
cancer and future directions. Therap Adv Gastroenterol. 10:631–645.
2017.
|
|
50
|
Margulis E, Slavutsky Y, Lang T, Behrens
M, Benjamini Y and Niv MY: BitterMatch: Recommendation systems for
matching molecules with bitter taste receptors. J Cheminform.
14:452022.
|
|
51
|
Melstrom LG, Salabat MR, Ding XZ, Milam
BM, Strouch M, Pelling JC and Bentrem DJ: Apigenin inhibits the
GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt
pathway in human pancreatic cancer cells. Pancreas. 37:426–431.
2008.
|
|
52
|
Wu DG, Yu P, Li JW, Jiang P, Sun J, Wang
HZ, Zhang LD, Wen MB and Bie P: Apigenin potentiates the growth
inhibitory effects by IKK-β-mediated NF-κB activation in pancreatic
cancer cells. Toxicol Lett. 224:157–164. 2014.
|
|
53
|
Li Q, Yang G, Feng M, Zheng S, Cao Z, Qiu
J, You L, Zheng L, Hu Y, Zhang T and Zhao Y: NF-kappaB in
pancreatic cancer: Its key role in chemoresistance. Cancer Lett.
421:127–134. 2018.
|
|
54
|
Kashyap P, Shikha D, Thakur M and Aneja A:
Functionality of apigenin as a potent antioxidant with emphasis on
bioavailability, metabolism, action mechanism and in vitro and in
vivo studies: A review. J Food Biochem. 46:e139502022.
|
|
55
|
Deyme L, Barbolosi D and Gattacceca F:
Population pharmacokinetics of FOLFIRINOX: A review of studies and
parameters. Cancer Chemother Pharmacol. 83:27–42. 2019.
|
|
56
|
Brierley JD, Gospodarowicz MK, Wittekind
C, et al: The TNM classification of malignant tumours 8. Oxford:
Wiley Blackwell; 2017
|
